NCT05342545Completed
Decision Support for Detection of Chronic Kidney Disease in Type II Diabetes Mellitus
Electronic Alert-Based Computerized Decision Support to Increase Detection of Chronic Kidney Disease in Patients With Type II Diabetes Mellitus (CKD-DETECT)
Source: ClinicalTrials.gov · Last updated 4 Nov 2025
Brief summary (registry, in English)
While data from the National Health and Nutrition Examination Survey (NHANES) estimate that 36.9% of patients with diabetes have CKD, only approximately 10% of patients are aware of their kidney disease. In its 2020 Standards of Medical Care in Diabetes, the ADA recommends that all patients with type II diabetes (T2DM) undergo annual measurement of urine albumin-to-creatinine ratio (UACR). The National Kidney Foundation (NKF) has also proposed an update to the requirements for assessment of adults with diabetes including both an estimated glomerular filtration rate (eGFR) and uACR. The goal of accurately identifying patients with T2DM and CKD is to help providers intervene at an earlier stage of kidney impairment, improve renal outcomes, and reduce associated healthcare costs. Failure to adopt these guideline recommendations has widespread implications, including underestimation of the burden of CKD in the T2DM population, delays in diagnosis of renal impairment, and ultimately, underutilization of therapies that could improve clinical outcomes. This single-center, 400-patient, randomized controlled trial will assess the impact of an EPIC Best Practice Advisory (BPA; alert-based CDS tool) on guideline-directed assessment for CKD using UACR in patients with T2DM who have not had a UACR in the past year.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 400 (actual)
- First submitted
- 18 Apr 2022
- Start date
- 1 Dec 2022
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT05342545
What you commit to
- Study type: Interventional
- Participants enrolled: 400
- From 1 Dec 2022 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- who are undergoing renal replacement therapy (either hemodialysis or peritoneal dialysis) as UACR will be unlikely to result in diagnosis change or therapeutic intervention OR
- who have undergone renal transplantation
Other
- have an established diagnosis of CKD (medical history, problem list, or visit diagnosis entry in the EHR) OR
Who the study is looking for
- BWH outpatients at least 18 years of age who are evaluated in Primary Care or Brigham Medical Specialties Clinics (Cardiovascular Medicine, Endocrinology, and Diabetology) AND
- have a diagnosis of T2DM AND
- have not had a UACR measured in the past year
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.